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Background: Data regarding the epidemiology of end-stage renal disease (ESRD) and dialysis in sub-Saharan Africa
are scarce and knowledge about the spectrum renal disease is very limited. This study is on the profile of patients
with ESRD in a referral hospital in Cameroon.
Methods: Medical records of patients with ESRD covering a 10-year period of activities of the Douala General
Hospital were reviewed. Data were retrieved on socio demographic, and clinical data such as major comorbidities,
the presumed aetiology of ESRD, blood pressure, biological variables and renal replacement therapy.
Results: In all 863 patients were included with 66% being men. Mean age was 47.4 years overall, 48.9 in men and
44.5 in women (p < 0.001). The main background aetiologies of ESRD were hypertension (30.9%), glomerulonephritis
(15.8%), diabetes (15.9%), HIV (6.6%) and unknown (14.7%). Participants with HIV, glomerulonephritis or unknown
background nephropathy were younger, more likely to be women, to be single and unemployed, while those with
hypertension and/or diabetes were older, more likely to be men, to be either married or widow, and to be retired
or working in the public sector. A total of 677 patients started haemodialysis with decreasing trend across age
quartiles (p = 009), and variation across background nephropathies (p < 0.001). Emergency dialysis unplanned on a
temporary catheter occurs in 88.3% of patients.
Conclusion: This study has revealed substantial gender and age differentials in the socio-demographic features and
background nephropathy in patients with ESRD in this setting. The likelihood of starting maintenance dialysis varied
across background nephropathies, driven at least in part by age differences across background nephropathies.Background
End-stage renal disease (ESRD) is a major public health
problem worldwide and is associated with considerable
morbidity and mortality [1,2]. It has been estimated that
the prevalence of ESRD will rise over the next decades,
driven by population aging, and increasing prevalence of
diabetes mellitus and hypertension [3,4]. This will occur
predominantly in developing countries [5-8], such as
those in sub-Saharan Africa (SSA), where poverty is ram-
pant [9,10]. In addition to non-communicable diseases,
communicable diseases especially infections (HIV, hepa-
titis) are common causes of CKD in Africa. Therefore the
epidemiology of ESRD is likely different in SSA, with
people affected at a much younger age [11-17]. Although
data are increasingly emerging to characterize the burden* Correspondence: patricehalle@yahoo.fr
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unless otherwise stated.of CKD in SSA [18-20], the profile of ERSD which is the
final common pathway for CKD, has yet to be optimally
described in most SSA settings. In Cameroon, renal
replacement therapy started in the early 1980, initially
in the Capital city (Yaounde), then was subsequently
extended to the economic capital (Douala), and more
recently (in 2008) to few other cities in the country
[21]. However, just likes in most other SSA countries,
nephrology services in Cameroon are not widely available
and are mostly understaffed. In 2012 for instance, the
country had a total of five nephrologists who were all
practicing in the two main cities of the country. In this
same year the country had eight hemodialysis centers pro-
viding care to about 500 patients with ESRD. Since the
year 2002, dialysis services are highly subsidized in public
centers [21]. One collateral effect of these measures has
been the increasing number of people with various stages
of CKD reporting to or referred to public institutions
with dialysis facilities. This provide the opportunity ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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tions with CKD, in the absence of large community
based-studies. Accordingly, the main purpose of this
study was to describe the profile of patients with
ESRD in Cameroon, using data from one of the major
referral hospital for ESRD in the country. Such infor-




The study was carried out in the renal unit of the Douala
general hospital (DGH) in Cameroon. DGH is tertiary
referral hospital with a capacity of 320 beds. It has the
largest haemodialysis unit of the country, and serves as
referral hospital for patients with kidney disease in the
Littoral region of the country (approximately 3 million
population in 2012) and beyond. Patients with kidney
disease referred to the unit are assigned a unique identifier
for the follow-up purpose. At the first consultation in
the unit and at dialysis initiation each patient has clin-
ical assessment and laboratory tests done. The center
has always functioned with one nephrologist and one
general practitioner except the period between 2005
and 2007 (2 nephrologists one general practitioner). At
the end of the year 2012, the unit was operating with one
nephrologist, two general practitioners and 12 nurses. The
center was equipped with 17 HD Fresenius® 4008S genera-
tors (Fresenius Medical Care, Hamburg, Germany), used
synthetic polysulfone dialysis membrane and bicarbonate
dialysate, and provided dialysis to 140 patients. All patients
underwent 2 dialysis sessions of 4 hour per week. The
study received administrative authorization from the
DGH and ethical approval was obtained from the Douala
University Ethics Committee. The study was based on
routinely collected data; accordingly individual informed
consent to participate does not apply.Patients and methods
This study was based on medical files of patients with
ESRD seen in the unit from January 2002 to December
2012. Of 1009 files retrieved 94 (9.3%) were excluded
for acute renal failure and 52 (5.1%) with ESRD for
missing data on kidney function. Therefore 863 pa-
tients (85.5% of the starting sample) were included in
the final analysis. For all patients the following data
were extracted: socio-demographic including age (in
years), sex, profession, marital status, and clinical data
such as major comorbidities (hypertension, diabetes,
HIV, gout, history of stroke) the presumed aetiology of
ESRD, blood pressure, biological variables, vascular access
at dialysis initiation, effective start of RRT, and reason for
non-initiation of dialysis.Operational definitions
The diagnosis of ESRD was based on the following: esti-
mated glomerular filtration rate (eGFR) based on the
Cockcroft and Gault formula (from 2002 to 2010) [22] or
the four-variable Modification of Diet in Renal Disease
(MDRD) formula (from 2010 and beyond) [23] lower than
15 ml/min/1.73 m2, bilateral shrunken kidneys on ultra-
sound and the presence of any of the following clinical or
biological signs of uraemia (anaemia, asthenia, anorexia,
vomiting, muscles cramps, hiccup, hypocalcaemia and
hyperphosphoremia) and need for chronic dialysis. Serum
creatinine measurements to estimate GFR used a kinetic
modification of the Jaffé reaction, with conversion to stan-
dardized values before implementation in the MDRD
equation as appropriate [24,25]. Hypertension, diabetes
and HIV were based on documented history, ongoing
drug treatments or a documented systolic (and/or dia-
stolic) blood pressure >140 (90) mmHg for hypertension
or fasting blood glucose >126 mg/dl, or a positive test
for HIV at baseline. The aetiology of kidney disease was
mostly based on clinical arguments in these patients
presenting late with CKD and in the context of unavail-
ability and/or unaffordability of renal histology. Chronic
glomerulonephritis was based either on a past history
of a documented glomerular disease or the presence of
a glomerular syndrome (proteinuria and/or haematuria,
hypertension in the absence of identifiable secondary
causes). Background nephropathy was ascribed to HIV
in the presence of a glomerular syndrome (nephrotic
range proteinuria, and/or haematuria) in an HIV positive
patient with hyperechogenic and normal size kidneys on
ultrasound, and in the absence of any other secondary
cause. Emergency dialysis was defined as dialysis initiation
unplanned in a life threatening situation (such as pulmon-
ary oedema, uremic encephalopathy, and severe hyperka-
laemia) on a temporary vascular access (non tunnelled
polyureththane double lumen central venous catheter).
The Charlson comorbidity score was estimated adding up
the scores assigned to existing comorbidities based on the
risk of dying associated with each of them. The following
comorbidities were considered: congestive heart failure,
coronary disease, diabetes mellitus, malignancies, stroke,
peripheral vascular disease, chronic obstructive pulmonary
disease, HIV/AIDS, chronic liver disease and connective
tissue disease [26].
Statistical analysis
Data were analysed with the use of Statistical Package
for Social Sciences SPSS® v.17 for Windows. We have
presented the results as count and percentages, mean
and standard deviation (SD). Groups’ comparisons used
the Student’s t-test, the analysis of the variance
(ANOVA), Mann–Whitney U test and Kruskal-Wallis
tests for continuous variables and chi-square tests and
Table 1 Profile of patients with ESRD overall over 10 years of the study
Variables Overall Male Female p-value Quartiles of age
Q1 Q2 Q3 Q4 p-trend
N (%) 863 (100) 570 (66.0) 293 (34.0) 205 (23.8) 218 (25.3) 221 (25.6) 219 (25.4)
Marital status, n (%) <0.001 <0.001
Single 169 (22.4) 93 (18.7) 76 (29.6) 120 (67.4) 31 (16.5) 14 (7.0) 4 (2.1)
Married 542 (71.9) 393 (79.1) 149 (58.0) 55 (30.9) 147 (27.1) 169 (84.9) 171 (90.5)
Divorced 3 (0.4) 1 (0.2) 2 (0.8) 0 1 (0.5) 1 (0.5) 1 (0.5)
Widow 40 (5.3) 10 (2.0) 30 (11.7) 3 (1.7) 9 (4.8) 15 (7.5) 13 (6.9)
Employment status, n (%) <0.001 <0.001
No employment 250 (33.1) 74 (15.8) 176 (67.5) 55 (30.2) 1 (0.5) 1 (0.5) 1 (0.5)
Private sector 186 (24.6) 147 (28.9) 39 (14.9) 48 (26.4) 71 (37.2) 44 (22.9) 23 (12.1)
Public sector 198 (26.2) 163 (33.0) 35 (13.4) 25 (13.7) 71 (37.2) 74 (38.5) 28 (14.7)
Retired 121 (16.0) 110 (22.3) 11 (4.2) 1 (0.5) 1 (0.5) 29 (15.1) 90 (47.4)
Mean age, yr. (SD) 47.4 (14.8) 48.8 (14.3) 44.5 (15.5) <0.001 26.3 (7.5) 43.8 (3.5) 53.3 (2.3) 64.6 (6.1) <0.001
Age, min-max, years 7.0-87.0 11.0-87.0 7.0-79.0 7.0-37.0 38.0-49.3 50.0-57.0 58.0-87.0
Age, median [25th-75th percentiles] 50 [38–58] 51 [41–58] 46 [32–56] 27 [20-32] 44 [41–47] 53 [51–55] 63 [60–68]
Any hypertension, n (%) 763 (88.4) 506 (88.8) 257 (87.7) 0.654 170 (82.9) 180 (82.6) 209 (94.6) 204 (93.2) <0.001
Any heart disease, n (%) 146 (16.9) 99 (17.4) 47 (16.0) 0.701 16 (7.8) 42 (19.3) 32 (14.5) 56 (25.6) <0.001
Diabetes, n (%) 245 (28.4) 177 (31.1) 68 (23.2) 0.017 9 (4.4) 38 (17.4) 102 (46.2) 96 (43.8) <0.001
HIV positive, n (%) 69 (8.0) 39 (6.8) 30 (10.2) 0.086 23 (11.2) 24 (11.0) 16 (7.2) 6 (2.7) <0.001
Alcohol drinker, n (%) 142 (16.5) 113 (19.8) 29 (9.9) <0.001 15 (7.3) 39 (17.9) 55 (24.9) 33 (15.1) 0.010
Smoking, n (%) 65 (7.5) 54 (9.5) 11 (3.8) 0.002 5 (2.4) 19 (8.7) 30 (13.6) 11 (5.0) 0.137
Cerebrovascular accidents, n (%) 20 (2.3) 16 (2.8) 4 (1.4) 0.235 1 (0.5) 4 (1.8) 9 (4.1) 6 (2.7) 0.053
Cancer, n (%) 12 (1.4) 5 (0.9) 7 (2.4) 0.120 2 (1.0) 5 (2.3) 3 (1.4) 2 (0.9) 0.731
Tuberculosis, n (%) 14 (1.6) 12 (2.1) 2 (0.7) 0.157 5 (2.4) 4 (1.8) 4 (1.8) 1 (0.5) 0.123
Mean Hb, g/dl (SD) 7.7 (1.9) 7.9 (2.0) 7.4 (1.8) 0.004 7.3 (1.8) 7.7 (2.1) 8.1 (1.9) 7.8 (1.8) 0.004
Mean Urea, mg/l (SD) 2.4 (1.1) 2.5 (1.2) 2.2 (1.0) 0.015 2.7 (1.1) 2.6 (1.2) 2.2 (1.0) 2.2 (1.1) <0.001
Mean creatinine,mg/l (SD) 171.3 (88.5) 175.8 (92.5) 162.6 (79.9) 0.064 198.0 (95.4) 185.9 (91.7) 160.9 (77.9) 142.4 (78.6) <0.001
Mean sodium, mmol/l (SD) 136.8 (11.3) 136.3 (11.6) 137.6 (10.5) 0.208 137.3 (10.8) 135.9 (13.5) 137.4 (8.9) 136.5 (11.4) 0.875
Mean potassium, mmol/l (SD) 5.3 (1.2) 5.3 (1.2) 5.3 (1.2) 0.774 5.3 (1.2) 5.4 (1.3) 5.2 (1.1) 5.3 (1.1) 0.890
Mean chlorine,mmol/l (SD) 100.8 (13.7) 100.4 (14.3) 101.6 (12.4) 0.347 101.2 (8.1) 100.3 (14.8) 100.6 (15.5) 101.2 (14.7) 0.938
Mean Ca2+,mg/l (SD) 80.0 (14.6) 80.1 (15.2) 80.0 (13.4) 0.842 75.6 (17.0) 81.0 (13.0) 79.7 (12.5) 83.7 (12.9) 0.001
Mean phosphate,mg/l (SD) 70.5 (37.4) 70.2 (32.9) 71.1 (45.0) 0.829 73.0 (36.1) 73.9 (42.5) 70.1 (29.5) 65.6 (40.9) 0.119
Dialysis start, n (%) 677 (78.4) 449 (78.8) 228 (77.8) 0.746 173 (84.4) 178 (81.7) 168 (76.0) 158 (72.1) 0.009
Background nephropathy, n (%) 0.021 <0.001
Hypertension 267 (30.9) 190 (33.3) 77 (26.3) 26 (12.7) 86 (39.4) 75 (33.9) 80 (36.6)
Diabetes 137 (15.9) 100 (17.5) 37 (12.6) 5 (2.4) 20 (9.2) 63 (28.5) 49 (22.4)
Hypertension and diabetes 65 (7.5) 44 (7.7) 21 (7.2) 4 (2.0) 5 (2.3) 24 (10.9) 32 (14.6)
Chronic glomerulonephritis 136 (15.8) 82 (14.4) 54 (18.4) 98 (47.8) 22 (10.1) 10 (4.5) 6 (2.7)
HIV 57 (6.6) 30 (5.3) 27 (9.2) 21 (10.2) 20 (9.2) 11 (5.0) 5 (2.3)
Others 74 (8.6) 48 (8.4) 26 (8.9) 12 (5.9) 20 (9.2) 21 (9.5) 21 (9.6)
Unknown 127 (14.7) 76 (13.3) 51 (17.4) 39 (19.0) 45 (20.6) 17 (7.7) 26 (11.9)
Median Charlson Score (Q1-Q3) 3 [2-4] 3 [2-4] 3 [2-4] 0.312 2 [2] 2 [2] 3 [3] 4 [4,5] <0.001
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Armitage trend test and Brown-Forsythe Levene proce-
dures were used to test the linearity of the trends
across quartiles of age. The level of significance was set
at p <0.05.
Results
Profile of participants overall and by gender
Eight hundred and sixty three patients were included
with 66% being men. The baseline characteristics of pa-
tients are shown in Table 1. Mean age was 47.4 years
overall, 48.9 in men and 44.5 in women (p < 0.001). In
all 71.9% (n = 542) of patients were married and the dis-
tribution of marital status was different between men
and women (p < 0.001). In all 33.1% (n = 250) were un-
employed, 24.6% (n = 186) were employed in the private
sector, 26.2% (n = 198) in the public sectors, while 16%
(n = 121) were retired. The employment status was sig-
nificantly different by gender (p < 0.001) with more men
working in the public and private sector, or being
employed while more women were unemployed. At
baseline 146 (16.9%) participants had history and/or
current heart disease, similarly in men and women (p =
0.701); 20 (2.3%) had a history of stroke (p = 0.235 for
men vs. women); 69 (8.0%) had a positive status for HIV
infection (p = 0.086); 14 (1.6%) had active tuberculosis
(p = 0.157); while 12 (1.4) had diagnosed cancer (p =
0.120). Furthermore 763 (88.4%) had hypertension, simi-
larly in men and women (p = 0.654); 245 (28.4%) had
diabetes mellitus (men vs. women: 32.1% vs. 23.2%; p =
0.017); while 142 (16.5%) were alcohol drinker en 65
(7.5%) smokers, with always higher prevalence in men
than in women (both p ≤ 0.002) The main background
aetiologies of ESRD were hypertension (30.9%, n = 267),
chronic glomerulonephritis (15.8%, n = 136), diabetes
(15.9%, n = 137) and HIV (6.6%, n = 57). No aetiology
was identified in 14.7% (n = 127) of the participants and
2.7% had a polycystic kidney disease. The distribution of
background aetiologies of CKD was significantly different
in men and women (p = 0.021), with more men having
hypertension, diabetes mellitus, while more women had
glomerulonephritis and HIV (Table 1). With the exception
of haemoglobin levels (p = 0.004) and urea levels (p =
0.015), the biological profile was generally similar in men
and women.
Profile of participants across age quartiles
Being married or widow increased across increasing age
quartiles while being single decreased (p < 0.001 for linear
trend). Mean haemoglobin (p = 0.004), creatinine (p <
0.001), calcium (p = 0.001) and Charlson score (p < 0.001)
linearly increased with age while urea (p < 0.001) and like-
lihood of starting dialysis (p = 0.009) linearly decreased
from 84.4% (173/205) in the lower age quartile to 72.1%(158/219) in the upper quartile. History of cerebrovascular
accident (p = 0.053), cancer (p = 0.731), tuberculosis (p =
0.123) and smoking (p = 0.137) were mostly non-linear
across age quarters while other risk factors and co-
morbidities varied in a linear fashion with age (all p ≤ 0.01
for linear trend). Hypertension, glomerulonephritis, HIV
infection and unknown aetiology for the background ne-
phropathy decreased with increasing age while diabetes
alone or with hypertension increased (p < 0.001, Table 1).
Profile of participants across background nephropathies
Participants with HIV, glomerulonephritis or unknown
background nephropathy were younger, more likely to
be women, to be single and unemployed, while those
hypertension, diabetes alone or with hypertension were
older (p < 0.001), more likely to be men (p = 0.021), to be
either married or widow (p < 0.001), and to be retired or
working in the public sector (p < 0.001). In general risk
factors and comorbidities varied significantly across
background nephropathies (all p ≤ 0.025), with the ex-
ception of cerebrovascular diseases (p = 0.089). There
was also significant differences across background ne-
phropathy subgroups for haemoglobin (p < 0.001), urea
(p < 0.001), creatinine (p < 0.001) phosphate (p = 0.024)
and Charlson score (p < 0.001), Table 2.
Dialysis start and variation across major subgroups
A total of 677 (78.4%) patients started haemodialysis
with no difference by sex (p = 0.746) but a significant
linearly decreasing trend across age quartiles (p = 009),
Table 1; and a significant variation across background
nephropathies (p < 0.001, Table 2). Variations in the dia-
lysis uptake across years was not significant (p = 0,246)
and did not follow a linear trend (p = 0,648 for linear
trend). The least dialysis initiation was observed in pa-
tients with diabetes (68.6%), followed by those with hyper-
tension (72.7%) and those with diabetes and hypertension
(76.9%) while the highest dialysis uptake was in patients
with unknown background nephropathy (91.3%). Reasons
for not starting dialysis among 181 (21.5%) participants
were financial constraints (53.8%), fear of dialysis (14%), or
the combination of both (8.1%), while the reason was un-
known in 24.2%. Reasons for not starting dialysis are
depicted in Figure 1 overall and by major subgroups show-
ing no difference between men and women (p = 0.175),
across age quartiles (p = 0.272) and across background ne-
phropathies (p = 0.735). Emergency dialysis unplanned on
a temporary catheter occurs in 88.3% of patients.
Discussion
Based on a large sample of patients treated in a tertiary
referral hospital, the current study provides information
on the profile of patients with ESRD in Cameroon.
These patients comprise mostly middle age men. One
Table 2 Profile of patients with ESRD by background nephropathy
Variables Hypertension Diabetes Diabetes
& HTN
Glomerulonephritis HIV Others Unknown p-value
N (%) 267 (30.9) 137 (15.9) 65 (7.5) 136 (15.8) 57 (6.6) 74 (8.6) 127 (14.7) NA
Men, n (%) 190 (71.2) 100 (73.0) 44 (67.7) 82 (60.3) 30 (52.6) 48 (64.9) 76 (59.8) 0.021
Marital status <0.001
Single 25 (10.9) 7 (5.7) 6 (10.5) 79 (59.8) 15 (27.8) 9 (14.1) 28 (29.5)
Married 193 (83.9) 110 (90.2) 44 (77.2) 49 (37.1) 31 (57.4) 52 (81.3) 63 (66.3)
Divorced 1 (0.1) 0 0 1 (0.8) 0 1 (1.6) 0
Widow 11 (1.5) 5 (4.1) 7 (12.3) 3 (2.3) 8 (1.1) 2 (14.8) 4 (4.2)
Employment status <0.001
No employment 52 (22.8) 27 (21.8) 14 (25.4) 80 (60.1) 16 (32) 17 (26.2) 44 (44)
Private sector 61 (26.8) 16 (12.9) 7 (12.7) 34 (25.6) 17 (34.0) 18 (27.7) 33 (33.0)
Public sector 74 (32.5) 45 (36.3) 16 (29.1) 17 (12.8) 15 (30.0) 14 (21.5) 17 (17.0)
Retired 41 (18.0) 36 (29.0) 18 (32.7) 2 (1.5) 2 (4.0) 16 (24.6) 6 (6.0)
Mean age, yr. (SD) 51.8 (11.9) 55.5 (10.1) 56.9 (10.5) 30.4 (13.5) 42.3 (10.4) 49.7 (12.1) 43.4 (14.4) <0.001
Any hypertension, n (%) 265 (99.3) 133 (97.1) 65 (100) 130 (95.6) 38 (66.7) 52 (10.3) 80 (63.0) <0.001
Any heart disease, n (%) 49 (18.4) 32 (23.4) 13 (20.0) 13 (9.6) 6 (10.5) 8 (10.8) 25 (19.7) 0.025
Diabetes, n (%) 19 (7.1) 135 (98.5) 64 (98.5) 6 (4.4) 6 (10.5) 7 (9.5) 8 (6.3) <0.001
HIV positive, n (%) 2 (0.7) 2 (1.5) 2 (3.1) 1 (0.7) 57 (100) 2 (2.7) 3 (2.4) <0.001
Alcohol drinker, n (%) 48 (18.0) 27 (19.7) 22 (33.8) 13 (9.6) 6 (10.5) 10 (13.5) 16 (12.6) 0.001
Smoking, n (%) 49 (18.4) 32 (23.4) 13 (20.0) 13 (9.6) 6 (10.5) 8 (10.8) 25 (19.7) 0.025
Cerebrovascular accidents, n (%) 9 (3.4) 3 (2.2) 4 (6.2) 2 (1.5) 1 (1.8) 1 (1.4) 0 0.089
Cancer, n (%) 2 (0.7) 0 1 (0.5) 0 0 7 (9.5) 2 (1.6) <0.001
Tuberculosis, n (%) 1 (0.4) 3 (2.2) 2 (3.1) 1 (0.7) 6 (10.5) 1 (1.4) 0 <0.001
Mean Hb, g/dl (SD) 7.8 (2.0) 8.4 (1.8) 7.7 (1.8) 7.2 (1.8) 7.6 (1.6) 7.7 (2.0) 7.3 (1.9) <0.001
Mean Urea, mg/l(SD) 2.4 (1.1) 1.9 (0.9) 2.2 (1.1) 2.2 (1.1) 2.6 (1.2) 2.3 (1.0) 2.9 (1.3) <0.001
Mean creatinine, mg/l (SD) 173.5 (88.5) 121.5 (62.5) 134.5 (50.8) 186.5 (83.0) 185.9 (84.5) 163.0 (83.4) 222.1 (105.3) <0.001
Mean sodium,mmol/l (SD) 136.9 (9.6) 136.7 (13.8) 140.1 (8.6) 137.1 (8.6) 135.6 (11.7) 134.0 (19.0) 136.1 (8.4) 0.217
Mean potassium, mmol/l (SD) 5.2 (1.3) 5.3 (1.0) 5.2 (1.2) 5.4 (1.3) 5.2 (1.2) 5.6 (1.0) 5.3 (1.1) 0.506
Mean chlorine, mmol/l (SD) 99.7 (13.9) 102.0 (13.8) 101.5 (21.7) 99.9 (12.9) 99.8 (9.1) 105.0 (11.9) 100.4 (10.4) 0.383
Mean Ca2+,mg/l (SD) 80.6 (13.3) 83.9 (12.0) 81.3 (12.5) 77.9 (15.2) 77.0 (12.9) 81.4 (12.5) 78.0 (18.0) 0.268
Mean phosphate,mg/l (SD) 73.1 (37.2) 56.1 (28.2) 71.2 (28.2) 71.9 (34.1) 76.5 (36.0) 70.5 (35.7) 79.3 (55.9) 0.024
Dialysis start, n (%) 194 (72.7) 94 (68.6) 50 (76.9) 116 (85.3) 44 (77.2) 63 (85.1) 116 (91.3) <0.001
Median Charlson Score (Q1-Q3) 3 [2,3] 3 [3,4] 3 [3,4] 2 [2] 6 [6,7] 3 [2-6] 2 [2,3] <0.001
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young patients were unemployed. Hypertension, dia-
betes, chronic glomerulonephritis and to some extend
HIV were the leading cause of ESRD. Across back-
ground nephropathies, participants with HIV, glomer-
ulonephritis or unknown aetiology were younger, more
likely to be women, to be single and unemployed, while
those with hypertension, diabetes alone or with hyper-
tension were older, more likely to be men, to be married
or widowed, and to be retired or employed. They present
as expected with abnormal biological profile, similarly in
men and women (with the exception of haemoglobinand urea levels) but with variation by background ne-
phropathy. Charlson comorbidity score increased with
age and background nephropathy with HIV patients
having the highest score. One in five patients eligible
for dialysis did not start such a treatment, while among
those who started, the rate of emergency dialysis on a
temporary catheter was very high.
In this study patients were relatively young, compared
with reports from developed countries were ESRD af-
fects more elderly people [27]; but our results are in
agreement with many reports from developing countries
[11-17,28]. This young age can be explain at least in part
Figure 1 Reasons for not starting dialysis in major subgroups. Figure panels are for major subgroups defined by gender (upper left panel),
quartiles of age (upper right panel) and background nephropathy (lower panel). Colour codes representing the different reasons for not starting
dialysis are for financial reasons alone (black), Fear of dialysis alone (diagonal blue accent lines), financial reasons and fear of dialysis (blue accent)
and unknown reasons (white). The broken horizontal lines have been added to assist visual interpretation of the figures. For each figure panel,
the number at the top of each bar are for the percentage of the corresponding reason within the subgroup. The p-value for the comparison of
the relevant subgroups are 0.175 for gender, 0.172 for quartiles of age and 0.735 for background nephropathy.
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ditions of young age such as glomerulonephritis and
HIV infections playing an important part in our setting.
Early occurrence in Blacks of some major risk factors
like hypertension, the low awareness, detection, treat-
ment and control of blood pressure likely contribute as
well [19,29-32]. But these may not explain the male
dominance among those with CKD in our setting. It is
however known that the male sex is a risk factor for
CKD and the male predominance among the ESRD
population is a worldwide phenomenon [33,34].
Based on clinical assessment alone, the finding in this
study of hypertension being the leading background ne-
phropathy, followed by chronic glomerulonephritis and
diabetes is consistent with previous studies from SSA.
[17,35,36]. Even if hypertensive nephrosclerosis is a more
prevalent in blacks in the absence of histology studies, it isunclear what proportion of hypertension in our sample
could be secondary to a primary renal disease. The high
proportion of ESRD from HIV nephropathy in women
and young people mirrors the demographic characteristics
of HIV infection in SSA [37,38].
Financial constraints is a known cause for not receiving
RRT in developing countries [39,40]. In this study one in
five participants could not start dialysis mainly due to fi-
nancial reasons. In Cameroon there is no social insurance
and most patients have to pay out of pocket for their
health cost. Despite the high state subsidies for dialysis
session (95%), the cost of out of pocket expenditure for
haemodialysis remain high and not affordable for most pa-
tients. The lack of awareness of the importance of RRT
and the absence of psychological preparation could ex-
plained the fear of dialysis. The need for early detection
and preventative measures with regard to CKD in our area
Halle et al. BMC Nephrology  (2015) 16:59 Page 7 of 8is obvious. The proportion of patients starting HD un-
planned, unprepared on a temporary access in this
study was among the highest reported so far. This is
mainly due to late presentation or referral of patients
to the nephrologist as it is already known in the study
setting.13 The adverse outcomes of unplanned dialysis
are well known and include increase morbidity, poor
quality of life and increased mortality [41-43].
Study strengths and limitations
The limitations of research based on health records have
been largely characterized, and apply for many to the
current study. It is however of note that there has been
effort to systematically collect in standardized fashions,
core data from patients with CKD and or commencing
dialysis in this setting, which limits the potentially effects
of missing data, and make data collection consistent
across years. The background nephropathy in this patients
largely reporting with advanced CKD was mostly based
on clinical arguments. Such an approach may not be all
accurate considering for instance that the differentiation
between hypertension causing ESRD and hypertension
resulting from or co-occurring with ESRD may not be
possible from a cross-sectional analysis of patients with
ESRD. The Cockcroft-Gault (CG) formula and MDRD
equation were used at different time-points to estimate
kidney function and confirm the diagnosis of ESRD. Com-
pared with MDRD (which is more accurate), CG tends to
overestimate kidney function, which in turn could falsely
lead to the classification of some patients with ESRD as
not having the condition. Such misclassification however
will have no effect on our findings and conclusions of the
current study. A major strength of the current study is the
large sample size which has allowed us to generate stable
estimates and make robust comparisons. Furthermore, the
study center remains the facility with the largest haemodi-
alysis unit in the country and has for most of the study
period been one of the two public hospitals with dialysis
facility. It is therefore very likely that the population
described in the current study is representative of the
population of people with ERSD in the country.
Conclusion
ESRD patients in Cameroon are relatively young and
comprised most men. Hypertension and diabetes were
the leading cause of ESRD, affecting more men and
older patients, while chronic glomerulonephritis and
HIV were common in women and young patients. A
considerable number of patients could not start dialysis
mainly for financial constraint in a setting where no
medical insurance exist; also the rate of unplanned
emergency dialysis was very high. All this emphasizes
the need for urgent measures to reduce the incidence of
ESRD in the country. This should focus on the preventionand treatment of risk factor especially diabetes, hyperten-
sion and infectious disease such as HIV. Sensitization,
continue medical education and the implementation of a
national program for prevention control of risk factors for
CKD and early detection of CKD are some measure to
undertake.
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